U.S., May 19 -- ClinicalTrials.gov registry received information related to the study (NCT07592767) titled 'RESvEraTrol in Parkinson's Disease (RESET)' on May 01.
Brief Summary: This is an exploratory phase 2a study to investigate two doses of resveratrol (JotrolTM) vs placebo in individuals diagnosed with Parkinson's Disease (PD). Participants (n=30) will be randomized 1:1:1 into 3 groups and will receive oral JotrolTM vs placebo. Study drug will be titrated to reach a final maximal dose per group and will be administered orally once daily (QD) for 3 months. The study will primarily evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics (PK/PD) of JotrolTM.
Study Start Date: June 01
Study Type: INTERVENTIONAL
Conditi...